XML 38 R27.htm IDEA: XBRL DOCUMENT v3.25.3

REVISIONS TO PREVIOUSLY ISSUED FINANCIAL STATEMENTS (Tables)

9 Months Ended

Sep. 30, 2025

Accounting Changes and Error Corrections [Abstract]

SCHEDULE OF REVISION ON THE PREVIOUSLY ISSUED CONSOLIDATED FINANCIAL STATEMENTS

 SCHEDULE OF REVISION ON THE PREVIOUSLY ISSUED CONSOLIDATED FINANCIAL STATEMENTS

		As Previously Reported				Adjustment				As Revised
		As of and for the Year Ended December 31, 2024
		As Previously Reported				Adjustment				As Revised
Consolidated Balance Sheet:
Accounts receivable		$	8,217,813			$	2,636,271			$	10,854,084
Other current assets		$	2,672,231			$	1,000,000			$	3,672,231
Total Current Assets		$	48,733,089			$	3,636,271			$	52,369,360
Total Assets		$	72,460,026			$	3,636,271			$	76,096,297
Accrued expenses		$	20,811,763			$	2,000,000			$	22,811,763
Deferred revenue		$	14,480,917			$	5,145,023			$	19,625,940
Total Current Liabilities		$	60,255,145			$	7,145,023			$	67,400,168
Total Liabilities		$	76,505,394			$	7,145,023			$	83,650,417
Accumulated deficit		$	236,253,218			$	3,597,713			$	239,850,931
Total LifeMD, Inc. Stockholders’ Deficit		$	5,485,501			$	3,597,713			$	9,083,214
Non-controlling interest		$	(1,440,133	)		$	(88,961	)		$	(1,529,094	)
Total Stockholders’ Deficit		$	4,045,368			$	3,508,752			$	7,554,120
Total Liabilities, Mezzanine Equity and Stockholder’s Deficit		$	72,460,026			$	3,636,271			$	76,096,297

		As Previously Reported				Adjustment				As Revised
Consolidated Statement of Operations:
Telehealth revenue, net		$	158,438,631			$	(3,614,556	)		$	154,824,075
Total revenues, net		$	212,453,838			$	(3,614,556	)		$	208,839,282
Gross profit		$	188,385,359			$	(3,614,556	)		$	184,770,803
General and administrative expenses		$	72,662,021			$	(1,482,913	)		$	71,179,108
Total expenses		$	204,530,040			$	(1,482,913	)		$	203,047,127
Operating loss		$	(16,144,681	)		$	(2,131,643	)		$	(18,276,324	)
Loss from operations before income taxes		$	(18,326,498	)		$	(2,131,643	)		$	(20,458,141	)
Net loss		$	(18,728,498	)		$	(2,131,643	)		$	(20,860,141	)
Net income attributable to noncontrolling interests		$	153,234			$	395,641			$	548,875
Net loss attributable to LifeMD, Inc.		$	(18,881,732	)		$	(2,527,284	)		$	(21,409,016	)
Net loss attributable to LifeMD, Inc. common stockholders		$	(21,987,982	)		$	(2,527,284	)		$	(24,515,266	)
Basic loss per share attributable to LifeMD, Inc. common stockholders		$	(0.53	)		$	(0.07	)		$	(0.60	)
Diluted loss per share attributable to LifeMD, Inc. common stockholders		$	(0.53	)		$	(0.07	)		$	(0.60	)
Consolidated Statement of Changes in Stockholders’ Equity (Deficit):
Accumulated deficit		$	236,253,218			$	3,597,713			$	239,850,931
Non-controlling interest		$	(1,440,133	)		$	(88,961	)		$	(1,529,094	)
Consolidated Statement of Cash Flows:
Net loss		$	(18,728,498	)		$	(2,131,643	)		$	(20,860,141	)
Accounts receivable		$	(2,940,563	)		$	(1,647,760	)		$	(4,588,323	)
Other current assets		$	(1,737,721	)		$	(1,000,000	)		$	(2,737,721	)
Deferred revenue		$	5,652,319			$	4,262,316			$	9,914,635
Accrued expenses		$	7,502,624			$	517,087			$	8,019,711
Net cash provided by operating activities		$	17,513,190			$	-			$	17,513,190

		As Previously Reported				Adjustment				As Revised
		For the Three Months Ended September 30, 2024
		As Previously Reported				Adjustment				As Revised
Condensed Consolidated Statement of Operations:
Telehealth revenue, net		$	40,275,546			$	(120,863	)		$	40,154,683
Total revenues, net		$	53,393,157			$	(120,863	)		$	53,272,294
Gross profit		$	48,379,616			$	(120,863	)		$	48,258,753
General and administrative expenses		$	18,925,844			$	(810,701	)		$	18,115,143
Total expenses		$	53,065,728			$	(810,701	)		$	52,255,027
Operating loss		$	(4,686,112	)		$	689,838			$	(3,996,274	)
Loss from operations before income taxes		$	(5,244,709	)		$	689,838			$	(4,554,871	)
Net loss		$	(5,477,232	)		$	689,838			$	(4,787,394	)
Net loss attributable to non-controlling interests		$	(345,767	)		$	216,295			$	(129,472	)
Net loss attributable to LifeMD, Inc.		$	(5,131,465	)		$	473,543			$	(4,657,922	)
Net loss attributable to LifeMD, Inc. common stockholders		$	(5,908,028	)		$	473,543			$	(5,434,485	)
Basic loss per share attributable to LifeMD, Inc. common stockholders		$	(0.14	)		$	0.01			$	(0.13	)
Diluted loss per share attributable to LifeMD, Inc. common stockholders		$	(0.14	)		$	0.01			$	(0.13	)

		As Previously Reported				Adjustment				As Revised
		As of and for the Nine Months Ended September 30, 2024
		As Previously Reported				Adjustment				As Revised
Condensed Consolidated Statement of Operations:
Telehealth revenue, net		$	108,549,257			$	1,137,797			$	109,687,054
Total revenues, net		$	148,199,266			$	1,137,797			$	149,337,063
Gross profit		$	133,560,633			$	1,137,797			$	134,698,430
General and administrative expenses		$	52,752,961			$	(1,592,078	)		$	51,160,883
Total expenses		$	150,723,556			$	(1,592,078	)		$	149,131,478
Operating loss		$	(17,162,923	)		$	2,729,875			$	(14,433,048	)
Loss from operations before income taxes		$	(18,730,666	)		$	2,729,875			$	(16,000,791	)
Net loss		$	(18,963,189	)		$	2,729,875			$	(16,233,314	)
Net (loss) income attributable to noncontrolling interests		$	(187,729	)		$	424,766			$	237,037
Net loss attributable to LifeMD, Inc.		$	(18,775,460	)		$	2,305,109			$	(16,470,351	)
Net loss attributable to LifeMD, Inc. common stockholders		$	(21,105,148	)		$	2,305,109			$	(18,800,039	)
Basic loss per share attributable to LifeMD, Inc. common stockholders		$	(0.52	)		$	0.06			$	(0.46	)
Diluted loss per share attributable to LifeMD, Inc. common stockholders		$	(0.52	)		$	0.06			$	(0.46	)
Condensed Consolidated Statement of Changes in Stockholders’ Equity (Deficit):
Accumulated deficit		$	235,370,384			$	(1,234,680	)		$	234,135,704
Non-controlling interest		$	(1,765,058	)		$	376,962			$	(1,388,096	)

		As Previously Reported				Adjustment				As Revised
Condensed Consolidated Statement of Cash Flows:
Net loss		$	(18,963,189	)		$	2,729,875			$	(16,233,314	)
Accounts receivable		$	(722,251	)		$	(4,450,283	)		$	(5,222,534	)
Other current assets		$	(1,303,495	)		$	(1,000,000	)		$	(2,303,495	)
Deferred revenue		$	7,561,943			$	3,312,487			$	10,874,430
Accrued expenses		$	7,704,036			$	(97,031	)		$	7,607,005
Net cash provided by operating activities		$	15,944,841			$	495,048			$	16,439,889
Distributions to non-controlling interest		$	(108,000	)		$	(495,048	)		$	(603,048	)
Net cash used in financing activities		$	(2,688,722	)		$	(495,048	)		$	(3,183,770	)

		As Previously Reported				Adjustment				As Revised
		As of and for the Three Months Ended March 31, 2025
		As Previously Reported				Adjustment				As Revised
Condensed Consolidated Statement of Operations:
Telehealth revenue, net		$	52,456,481			$	(1,568,582	)		$	50,887,899
Total revenues, net		$	65,697,756			$	(1,568,582	)		$	64,129,174
Gross profit		$	57,054,040			$	(1,568,582	)		$	55,485,458
Operating income		$	2,542,924			$	(1,568,582	)		$	974,342
Net income		$	1,916,649			$	(1,568,582	)		$	348,067
Net income (loss) attributable to LifeMD, Inc.		$	1,384,804			$	(1,568,582	)		$	(183,778	)
Net income (loss) attributable to LifeMD, Inc. common stockholders		$	608,241			$	(1,568,582	)		$	(960,341	)
Basic earnings (loss) per share attributable to LifeMD, Inc. common stockholders		$	0.01			$	(0.03	)		$	(0.02	)
Diluted earnings (loss) per share attributable to LifeMD, Inc. common stockholders		$	0.01			$	(0.03	)		$	(0.02	)
Condensed Consolidated Statement of Changes in Stockholders’ Equity (Deficit):
Accumulated deficit		$	235,644,977			$	5,166,295			$	240,811,272
Non-controlling interest		$	(1,935,978	)		$	(88,961	)		$	(2,024,939	)
Condensed Consolidated Statement of Cash Flows:
Net income		$	1,916,649			$	(1,568,582	)		$	348,067
Accounts receivable			(1,974,961	)			1,507,106				(467,855	)
Deferred revenue			144,985				61,475				206,460
Net cash provided by operating activities		$	3,068,387			$	-			$	3,068,387

		As Previously Reported				Adjustment				As Revised
		For the Three Months Ended June 30, 2025
		As Previously Reported				Adjustment				As Revised
Condensed Consolidated Statement of Operations:
Telehealth revenue, net		$	48,563,672			$	455,210			$	49,018,882
Total revenues, net		$	62,218,185			$	455,210			$	62,673,395
Gross profit		$	54,787,281			$	455,210			$	55,242,491
Operating loss		$	(906,772	)		$	455,210			$	(451,562	)
Net loss		$	(1,569,799	)		$	455,210			$	(1,114,589	)
Net loss attributable to LifeMD, Inc.		$	(2,074,874	)		$	455,210			$	(1,619,664	)
Net loss attributable to LifeMD, Inc. common stockholders		$	(2,851,436	)		$	455,210			$	(2,396,226	)
Basic loss per share attributable to LifeMD, Inc. common stockholders		$	(0.06	)		$	0.01			$	(0.05	)
Diluted loss per share attributable to LifeMD, Inc. common stockholders		$	(0.06	)		$	0.01			$	(0.05	)

		As Previously Reported				Adjustment				As Revised
		As of and for the Six Months Ended June 30, 2025
		As Previously Reported				Adjustment				As Revised
Condensed Consolidated Statement of Operations:
Telehealth revenue, net		$	101,020,153			$	(1,113,372	)		$	99,906,781
Total revenues, net		$	127,915,941			$	(1,113,372	)		$	126,802,569
Gross profit		$	111,841,321			$	(1,113,372	)		$	110,727,949
Operating income		$	1,636,152			$	(1,113,372	)		$	522,780
Operating income (loss)			1,636,152				(1,113,372	)			522,780
Net income (loss)		$	346,850			$	(1,113,372	)		$	(766,522	)
Net loss attributable to LifeMD, Inc.		$	(690,070	)		$	(1,113,372	)		$	(1,803,442	)
Net loss attributable to LifeMD, Inc. common stockholders		$	(2,243,195	)		$	(1,113,372	)		$	(3,356,567	)
Basic loss per share attributable to LifeMD, Inc. common stockholders		$	(0.05	)		$	(0.03	)		$	(0.08	)
Diluted loss per share attributable to LifeMD, Inc. common stockholders		$	(0.05	)		$	(0.03	)		$	(0.08	)
Condensed Consolidated Statement of Changes in Stockholders’ Equity (Deficit):
Accumulated deficit		$	238,496,413			$	4,711,085			$	243,207,498
Non-controlling interest		$	(2,164,934	)		$	(88,961	)		$	(2,253,895	)
Condensed Consolidated Statement of Cash Flows:
Net income (loss)		$	346,850			$	(1,113,372	)		$	(766,522	)
Accounts receivable		$	887,684			$	645,683			$	1,533,367
Deferred revenue		$	(2,690,893	)		$	(32,312	)		$	(2,723,205	)
Accrued expenses		$	(5,865,264	)		$	500,000			$	(5,365,264	)
Net cash provided by operating activities		$	11,707,834			$	-			$	11,707,834

X

- References

No definition available.

+ Details

Name:	us-gaap_AccountingChangesAndErrorCorrectionsAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of prior period adjustments to previously issued financial statements including (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustments (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-7

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9

+ Details

Name:	us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration